Tom Denee

421 total citations
21 papers, 266 citations indexed

About

Tom Denee is a scholar working on Molecular Biology, Pharmacology and Social Psychology. According to data from OpenAlex, Tom Denee has authored 21 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pharmacology and 6 papers in Social Psychology. Recurrent topics in Tom Denee's work include Retinal Development and Disorders (6 papers), Treatment of Major Depression (6 papers) and Mental Health Treatment and Access (6 papers). Tom Denee is often cited by papers focused on Retinal Development and Disorders (6 papers), Treatment of Major Depression (6 papers) and Mental Health Treatment and Access (6 papers). Tom Denee collaborates with scholars based in United Kingdom, Netherlands and France. Tom Denee's co-authors include Benoît Rive, Dena H. Jaffe, Cicely Kerr, Jan Sermon, Cornelis L. Mulder, Bart Malfait, Thomas R. Einarson, Mark Lamotte, Basil G. Bereza and Michel Goldman and has published in prestigious journals such as PLoS ONE, Nature Reviews Drug Discovery and Journal of Affective Disorders.

In The Last Decade

Tom Denee

16 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tom Denee United Kingdom 7 125 82 69 56 47 21 266
Pedro Such Denmark 11 135 1.1× 307 3.7× 40 0.6× 37 0.7× 73 1.6× 32 486
R. Taylor United Kingdom 9 173 1.4× 108 1.3× 81 1.2× 27 0.5× 52 1.1× 20 291
Hideaki Tani Japan 12 57 0.5× 184 2.2× 35 0.5× 44 0.8× 97 2.1× 36 384
Rocco Nicola Forgione Italy 10 118 0.9× 266 3.2× 45 0.7× 38 0.7× 105 2.2× 12 440
Maria Tome United Kingdom 9 143 1.1× 129 1.6× 28 0.4× 27 0.5× 64 1.4× 17 458
Nicola Casacalenda Canada 7 64 0.5× 119 1.5× 29 0.4× 79 1.4× 126 2.7× 9 324
André Elferink Netherlands 9 70 0.6× 79 1.0× 18 0.3× 21 0.4× 56 1.2× 16 278
Joan Buttenfield United States 8 82 0.7× 172 2.1× 39 0.6× 34 0.6× 112 2.4× 10 363
S. Troy France 8 155 1.2× 169 2.1× 37 0.5× 25 0.4× 39 0.8× 15 313
Elizabeth A. Whitham United States 10 99 0.8× 231 2.8× 66 1.0× 27 0.5× 57 1.2× 14 342

Countries citing papers authored by Tom Denee

Since Specialization
Citations

This map shows the geographic impact of Tom Denee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Denee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Denee more than expected).

Fields of papers citing papers by Tom Denee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Denee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Denee. The network helps show where Tom Denee may publish in the future.

Co-authorship network of co-authors of Tom Denee

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Denee. A scholar is included among the top collaborators of Tom Denee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Denee. Tom Denee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Parmeggiani, Francesco, Dominique Brémond‐Gignac, Avril Daly, et al.. (2025). The burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes (PROs): findings from the EXPLORE XLRP-2 study. Eye. 39(3). 578–585. 2 indexed citations
2.
Parmeggiani, Francesco, Dominique Brémond‐Gignac, Avril Daly, et al.. (2025). The Impacts of Caregiving for Patients with X-Linked Retinitis Pigmentosa (XLRP): Findings from the EXPLORE XLRP-2 Study. Advances in Therapy. 42(6). 2922–2936.
3.
Matza, Louis S., Nan Li, Katie D. Stewart, et al.. (2025). Health state utilities associated with X-linked retinitis pigmentosa (XLRP). The European Journal of Health Economics. 26(7). 1263–1273.
4.
5.
6.
Denee, Tom, et al.. (2024). Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?. Value in Health. 28(1). 116–124. 1 indexed citations
7.
Matza, Louis S., Na Li, Katie D. Stewart, et al.. (2023). PCR193 Health State Utilities Associated with X-Linked Retinitis Pigmentosa in the United Kingdom. Value in Health. 26(12). S486–S486.
8.
Kerr, Cicely, et al.. (2023). The lived experience of major and treatment-resistant depression in England: a mixed-methods study. Acta Psychologica. 240. 104035–104035. 1 indexed citations
9.
10.
11.
Denee, Tom, et al.. (2022). The impact of treatment-resistant depression on the lives of carers: A mixed-methods study. Journal of Affective Disorders. 325. 194–205. 5 indexed citations
12.
13.
14.
Denee, Tom, John Waller, Tom Bailey, et al.. (2020). A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. Current Medical Research and Opinion. 37(2). 311–319. 6 indexed citations
15.
Jaffe, Dena H., Benoît Rive, & Tom Denee. (2019). The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 19(1). 247–247. 153 indexed citations
16.
Jaffe, Dena H., Benoît Rive, & Tom Denee. (2019). <p>The burden of suicidal ideation across Europe: a cross-sectional survey in five countries</p>. Neuropsychiatric Disease and Treatment. Volume 15. 2257–2271. 16 indexed citations
17.
Denee, Tom, et al.. (2018). PMH73 - THE BURDEN OF TREATMENT-RESISTANT DEPRESSION IN EUROPE FROM THE PATIENT PERSPECTIVE. Value in Health. 21. S286–S286. 1 indexed citations
18.
Einarson, Thomas R., et al.. (2017). Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. Journal of Medical Economics. 20(11). 1187–1199. 17 indexed citations
19.
Sermon, Jan, et al.. (2017). Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. PLoS ONE. 12(6). e0179049–e0179049. 21 indexed citations
20.
Denee, Tom, et al.. (2016). Conceptual framework for outcomes research studies of hepatitis C: an analytical review. Infection and Drug Resistance. 9. 101–101.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pedro Such Breakdown of academic impact, for papers by R. Taylor Breakdown of academic impact, for papers by Hideaki Tani Breakdown of academic impact, for papers by Rocco Nicola Forgione Breakdown of academic impact, for papers by Maria Tome Breakdown of academic impact, for papers by Nicola Casacalenda Breakdown of academic impact, for papers by André Elferink Breakdown of academic impact, for papers by Joan Buttenfield Breakdown of academic impact, for papers by S. Troy Breakdown of academic impact, for papers by Elizabeth A. Whitham
Rankless by CCL
2026